GLP-1 Drugs and Sudden Vision Loss (NAION) — the Safety Signal Explained

What is NAION?

Non-arteritic anterior ischaemic optic neuropathy (NAION) is sudden vision loss caused by a temporary drop in blood supply to the head of the optic nerve — the cable that carries sight from the eye to the brain. It is the most common cause of sudden optic-nerve-related vision loss in adults over 50. The MHRA describes it as “sudden, painless vision loss, usually in one eye” that is often experienced as blurring or cloudiness. Key features:

• Sudden onset, often first noticed on waking, and usually in one eye.
• Typically painless — there is no red, sore or gritty eye to warn you.
• The vision loss is usually permanent; there is no proven treatment to reverse it, which is why prompt assessment to exclude other, treatable causes matters.
• People with a small, “crowded” optic disc (an anatomical trait sometimes called a “disc at risk”) are more susceptible, as are people with diabetes, high blood pressure and sleep apnoea.

What the studies actually found

The signal is real, but the picture is genuinely mixed — and honesty about that matters. The concern began with a 2024 study from a specialist eye centre and grew as larger datasets were examined. The most consistent finding comes from national registries and pooled analyses:

• A large Danish cohort of people with type 2 diabetes found that once-weekly semaglutide was associated with roughly a doubling of the five-year risk of NAION compared with non-users (PMID 39696569).
• A Danish–Norwegian registry study reported a hazard ratio of about 2.8 versus a comparator diabetes drug, with an absolute incidence of roughly 2–3 cases per 10,000 person-years (PMID 40098249).
• A 2026 meta-analysis of 15 studies covering more than 1.5 million patients found an odds ratio of about 1.7 for GLP-1 medicines and NAION — but the absolute excess was tiny, on the order of one extra case per several thousand people treated (PMID 41498755).

Against those findings, several large population studies found no significant increase — and a few even found a lower rate — particularly when semaglutide users were compared with people on other modern diabetes drugs rather than with untreated people. That comparison matters because of confounding: diabetes, obesity, high blood pressure and sleep apnoea are all independent risk factors for NAION, and they are exactly the conditions these medicines are prescribed for. Some of the raw association may reflect who takes the drug rather than the drug itself. Regulators weighed all of this and concluded the signal was real but small enough to classify as “very rare”.

What the regulators have done

This is not a rumour or a lawsuit talking point — it is an official regulatory conclusion:

• EMA (Europe), June 2025: The EMA's safety committee (PRAC) reviewed all available data and recommended that the product information for semaglutide medicines be updated to list NAION as a side effect with a frequency of “very rare” (up to 1 in 10,000). It noted an approximately two-fold relative risk and about one extra case per 10,000 person-years, with no identified time window for when it might occur.
• MHRA (UK), 5 February 2026: The MHRA issued a Drug Safety Update confirming NAION has been very rarely reported with semaglutide (Ozempic, Rybelsus and Wegovy), advised urgent ophthalmology referral for anyone with sudden vision loss, and said the UK Summary of Product Characteristics and Patient Information Leaflets would be updated to describe the risk.

Importantly, neither regulator advised people to stop taking semaglutide. The action is about informed consent and prompt response to symptoms, not withdrawal of the medicine. For a plain-English overview, the MHRA also publishes GLP-1 medicines: what you need to know.

Is this a class effect for all GLP-1 drugs?

On current evidence, no — the regulatory action is specific to semaglutide. The vast majority of reported cases and the strongest statistical signals involve semaglutide. Reports for other GLP-1 medicines, including tirzepatide (Mounjaro), liraglutide and dulaglutide, are far fewer. Whether that reflects a true difference in the drugs or simply that semaglutide has been on the market longer and in far greater numbers is not yet settled. What this means in practice: if you take a non-semaglutide GLP-1 medicine, the same red-flag advice still applies — sudden vision loss always warrants urgent assessment — but the specific NAION labelling change to date concerns semaglutide.

What this does and does not mean for you

• Do not stop your medicine on your own. For most people the proven cardiovascular and metabolic benefits of these medicines outweigh a very rare eye risk. Stopping suddenly has its own consequences — discuss any concern with your prescriber first.
• Know the one symptom that matters. Sudden loss or blurring of vision — usually painless, usually one eye — is the red flag. Treat it as an emergency and get urgent eye assessment.
• Mention your eye history. If you have already had NAION in one eye, or have been told you have a small/crowded optic disc, tell your prescriber before starting or continuing semaglutide so they can weigh it up with you.
• Report side effects. Any suspected reaction can be reported through the MHRA Yellow Card scheme — this is how signals like this one are detected.
• Beware fakes. Only obtain GLP-1 medicines from a UK-registered pharmacy against a valid prescription. Never buy from unregulated online sellers.

This guide deliberately gives no dosing information. Semaglutide and other GLP-1 medicines should only ever be started, adjusted or stopped under a prescriber. If you are unsure or unwell, speak to your pharmacist or GP, call NHS 111, or for sudden vision loss go to eye casualty or A&E. For a general overview of the medicine, see the NHS page on semaglutide.

Track supply of these medicines

MediWatch monitors official UK supply signals for these products. Check the live pages for semaglutide, Ozempic, Wegovy and Mounjaro.

Related reading